Department of Radiology
Found 27 results
Filters: Author is Osborne, Joseph R  [Clear All Filters]
2024
Ivanidze J, Chang SJung, Haghdel A, Kim JTae, RoyChoudhury A, Wu A, Ramakrishna R, Schwartz TH, Cisse B, Stieg P et al..  2024.  [Ga68] DOTATATE PET/MRI-Guided Radiosurgical Treatment Planning and Response Assessment in Meningiomas.. Neuro Oncol.
2023
Kim SH, Chang SJung Chris, Dobri G, Strauss S, Lin E, Zavaletta V, Pannullo SC, Osborne JR, Schwartz TH, Knisely JPS et al..  2023.  [68 Ga]-DOTATATE PET/MR-based evaluation of physiologic somatostatin receptor 2 expression in the adult pituitary gland as a function of age and sex in a prospective cohort.. Pituitary. 26(4):419-428.
Subramanian K, Martinez J, Castellanos SHuicochea, Ivanidze J, Nagar H, Nicholson S, Youn T, Nauseef JT, Tagawa S, Osborne JR.  2023.  Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men.. Sci Rep. 13(1):8321.
Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L et al..  2023.  Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).. Eur J Nucl Med Mol Imaging. 50(9):2830-2845.
Osborne JR.  2023.  Predictive Value of Genomic Classifier Scores and Transcriptomic Data for Prostate Cancer Distant Metastasis Risk: A Multicenter Retrospective Study..
Stangl-Kremser J, Sun M, Ho B, Thomas J, Nauseef JT, Osborne JR, Molina A, Sternberg CN, Nanus DM, Bander NH et al..  2023.  Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.. Prostate. 83(14):1351-1357.
Subramanian K, Osborne JR.  2023.  PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary.. Eur J Nucl Med Mol Imaging. 50(12):3509-3510.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K et al..  2023.  PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.. Eur J Nucl Med Mol Imaging. 50(5):1466-1486.
Osborne JR.  2023.  Randomized Trial of Five or Two MRI-guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT)..
Stangl-Kremser J, Ricaurte-Fajardo A, Subramanian K, Osborne JR, Sun M, Tagawa ST, Bander NH.  2023.  Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.. Prostate. 83(10):901-911.
Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST et al..  2023.  SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.. J Nucl Med. 64(9):1417-1423.
Lazzaro A, Albury J, Hume E, Osborne JR, Islam JY, Camacho-Rivera M.  2023.  Social and Demographic Influences of Trust in Cancer Information Among Brooklyn, New York Residents.. J Community Health.
Lazzaro A, Albury J, Hume E, Osborne JR, Islam JY, Camacho-Rivera M.  2023.  Social and Demographic Influences of Trust in Cancer Information Among Brooklyn, New York Residents.. J Community Health.
Bodei L, R Tuttle M, Grewal RK, Mauguen A, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VSudar, Osborne JR, Haque S et al..  2023.  Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs.. Eur J Nucl Med Mol Imaging.
Subramanian K, Stangl-Kremser J, Sawoszczyk L, Avlonitis V, Gernerd A, Nixon K, Zgaljardic M, Tagawa S, Bander N, Osborne JR.  2023.  α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.. J Nucl Med Technol. 51(3):215-219.
2022
Ivanidze J, Roytman M, Skafida M, Kim S, Glynn S, Osborne JR, Pannullo SC, Nehmeh S, Ramakrishna R, Schwartz TH et al..  2022.  Dynamic Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas.. Radiol Imaging Cancer. 4(2):e210067.
2021
Mahase SS, O'Brien DARoth, No D, Roytman M, Skafida ME, Lin E, Karakatsanis NA, Osborne JR, Brandmaier A, Pannullo SC et al..  2021.  [Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas.. Neurooncol Adv. 3(1):vdab012.
Ford JN, Sweeney EM, Skafida M, Glynn S, Amoashiy M, Lange DJ, Lin E, Chiang GC, Osborne JR, Pahlajani S et al..  2021.  Heuristic scoring method utilizing FDG-PET statistical parametric mapping in the evaluation of suspected Alzheimer disease and frontotemporal lobar degeneration.. Am J Nucl Med Mol Imaging. 11(4):313-326.
Roytman M, Kim S, Glynn S, Thomas C, Lin E, Feltus W, Magge RS, Liechty B, Schwartz TH, Ramakrishna R et al..  2021.  PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes.. Front Oncol. 11:820287.
2020
Ivanidze J, Skafida M, Pandya S, Patel D, Osborne JR, Raj A, Gupta A, Henchcliffe C, Dyke JP.  2020.  Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease.. Front Neurosci. 14:528809.
2019
Chaker S, Al-Dasuqi K, Baradaran H, Demetres M, Delgado D, Nehmeh S, Osborne JR, Christos PJ, Kamel H, Gupta A.  2019.  Carotid Plaque Positron Emission Tomography Imaging and Cerebral Ischemic Disease.. Stroke. 50(8):2072-2079.
Ivanidze J, Roytman M, Lin E, Magge RS, Pisapia DJ, Liechty B, Karakatsanis N, Ramakrishna R, Knisely J, Schwartz TH et al..  2019.  Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas.. J Neuroimaging. 29(5):650-656.
2018
Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW et al..  2018.  Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.. JAMA Oncol. 4(2):217-224.
2016
Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR et al..  2016.  Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling.. EJNMMI Res. 6(1):7.
2015
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AMak et al..  2015.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.. Clin Cancer Res. 21(23):5277-85.